Daratumumab (Darzalex®) for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 09/10/17 |
| Rapid review completed | 27/11/17 |
| Rapid Review Outcome | A full pharmacoeconomic evaluation is recommended. |